| Literature DB >> 35290369 |
Ali Mirzazadeh1, Ingrid Eshun-Wilson2, Ryan R Thompson3, Atousa Bonyani4, James G Kahn5, Stefan D Baral6, Sheree Schwartz6, George Rutherford1, Elvin H Geng2,7.
Abstract
BACKGROUND: Optimizing services to facilitate engagement and retention in care of people living with HIV (PLWH) on antiretroviral therapies (ARTs) is critical to decrease HIV-related morbidity and mortality and HIV transmission. We systematically reviewed the literature for the effectiveness of implementation strategies to reestablish and subsequently retain clinical contact, improve viral load suppression, and reduce mortality among patients who had been lost to follow-up (LTFU) from HIV services. METHODS ANDEntities:
Mesh:
Year: 2022 PMID: 35290369 PMCID: PMC8923443 DOI: 10.1371/journal.pmed.1003940
Source DB: PubMed Journal: PLoS Med ISSN: 1549-1277 Impact factor: 11.613
Characteristics of included studies.
| Study | Country | Income | Design | N | Sex | Age | % Male | % MSM | % PWID | LTFU definition |
|---|---|---|---|---|---|---|---|---|---|---|
| Alamo 2012 | Uganda | LMIC | Cohort | 579 | All | Adult | 40% | Absence from the clinic for 90 days after the expected last clinic visit | ||
| Alizadeh 2019 | Uganda | LMIC | Cohort | 691 | Missed 2 monthly appointments (either pre- or post-ART initiation) | |||||
| Ardura-Garcia 2015 | Malawi | LMIC | Cohort | 251 | All | Peds | 47% | Missed an scheduled appointment for ART collection of 3 weeks or more | ||
| Bean 2017 | USA | HIC | Cohort | 233 | All | Adult | 77% | Not retained in care for 1 year | ||
| Beres 2019 | Zambia | LMIC | RCT | 37,933 | All | Adult | 40% | Visit gap of >90 days from their last appointment | ||
| Bershetyn 2017 | Uganda, Kenya, Tanzania | LMIC | RCT | 5,781 | All | Adult | 35% | LTFU (>90 days late for last visit) | ||
| Bove 2015 | USA | HIC | Cohort | 1,399 | All | Adult | 84% | 39% | 20% | No CD4 or VLs reported for > = 1 year |
| Bupamba 2010 | Tanzania | LMIC | Cohort | 966 | All | Missing 3 consecutive appointments | ||||
| Chang 2019 | USA | HIC | Cohort | 408 | All | All | 86.0% | 55.0% | 10.0% | No CD4 or VL reported to surveillance for≥12 months or a VL of>500 copies/mL at last report ≥6 months after HIV diagnosis. |
| Chikuse 2019 | Malawi | LMIC | Cohort | 5,651 | All | Missed appointment and lost for unknown duration | ||||
| Deery 2014 | South Africa | LMIC | Cohort | 755 | All | 38% | No ART drug pickup within 1 month of the scheduled refill date | |||
| Donovan 2018 | USA | HIC | Cohort | 1,118 | All | Adult | 70% | 40% | 9% | Lack of attendance at a medical visit in the prior 6–9 months |
| Dufour 2018 | UK | HIC | Cohort | 377 | All | Patients not seen in the HIV service for ≥8 months and without future appointments | ||||
| Edwards 2019 | Trinidad and Tobago | LMIC | Cohort | 1,058 | All | All | 50% | 12% | Patients who were not active in care for 3 months or more | |
| Fanfair 2019 | USA | HIC | RCT | 1,894 | All | Adult | 74% | 45% | 20% | No CD4 or VL result in surveillance data for ≥6 months and no clinic visit for ≥6 months |
| Fernández-Luis 2019 | Mozambique | LMIC | Cohort | 269 | All | Children | 59.7% | Not attending the clinic for 120 days after last attended visit | ||
| Fox 2018 | South Africa | LMIC | RCT | 1,266 | All | Adult | 40% | No return for scheduled appointment within 5 to 90 days of appointment date | ||
| Healey 2018 | Australia | HIC | Cohort | 44 | All | Adult | 87% | 80% | Patient not having attended for >4 months | |
| Keller 2017 | USA | HIC | Cohort | 452 | All | Adult | 69% | 46% | 7% | Not attend clinic appointment for >9 months |
| Kunzweiler 2019 | USA | HIC | Cohort | 1,418 | All | Adult | 69.9% | 27.7% | 22.9% | No CD4 or VL test completed in the previous 6 months] or no CD4 or VL test completed within 3 months of being diagnosed |
| Lubelcheck 2016 | USA | HIC | Cohort | 55 | All | Adult | 73% | 41% | No primary care visit in 7 months | |
| Magnus 2012 | USA | HIC | Cohort | 419 | All | Adult | 63% | 14% | 4% | No CD4 or HIV VL monitoring in >1 year |
| McMahon 2015 | Australia | HIC | Cohort | 167 | All | 92% | 67% | No VL in 9 months | ||
| Nabaggala 2018 | Uganda | LMIC | Cohort | 381 | All | 32% | Missed a scheduled visit | |||
| Naidoo 2019 | South Africa | LMIC | Cohort | 864 | All | All | 27% | 1 or more missed monthly or biweekly visits | ||
| Nakiwogga-Muwanga 2015 | Uganda | LMIC | Cohort | 256 | All | Adult | 41% | Missed clinic appointment for 8–90 days | ||
| Rebeiro 2017 | Kenya | LMIC | Cohort | 34,522 | All | Adult | 32% | Missed scheduled appointment | ||
| Saafir-Callaway 2020 | USA | HIC | Cohort | 686 | All | Adult | 68.0% | 42.7% | 12.6% | No VL result, CD4 result, or care visit for the immediate past 6–12 months |
| Sharp 2019 | USA | HIC | Cohort | 166 | All | Adult | 70.0% | No CD4 or HIV-1 RNA tests during the last 14 months | ||
| Sitapati 2012 | USA | HIC | Cohort | 716 | All | All | 86% | 62% | 13% | Gaps in care for more than 6 months |
| Tesoriero 2017 | USA | HIC | Cohort | 1,155 | All | Adult | 61% | 37% | 14% | No prognostic or diagnostic laboratory results (VL, CD4, or genotype) in the prior 13 to 24 months |
| Tweya 2010 | Malawi | LMIC | Cohort | 3,098 | All | All | 44% | Missed clinic appointments by >3 weeks | ||
| Udeagu 2013 | USA | HIC | Cohort | 797 | All | All | 55% | 15% | 35% | No CD4 or VL during the most recent 9 months |
| Udeagu 2018 | USA | HIC | Cohort | 1,218 | All | Adult | 59% | 23% | 23% | No laboratory reports in the last 9 months |
| Udeagu 2019 | USA | HIC | RCT | 3,604 | All | 52% | 21% | 10% | No HIV VL or CD4 cell count > = 9 months | |
| Villanueva 2019 | USA | HIC | RCT | 655 | All | 62% | 30% | 31% | “In-care” for 12 months followed by “out-of-care” for 6 months | |
| Wohl 2016 | USA | HIC | Cohort | 1,139 | All | Adult | 78% | 50% | 33% | No HIV care visits in 6–12 months and last VL >200 copies per milliliter or no HIV care visits in 12 months |
ART, antiretroviral therapy; HIC, high-income country; LMIC, low- and middle-income country; LTFU, lost to follow-up; MSM, men who have sex with men; PWID, people who inject drugs; RCT, randomized controlled trial; VL, viral load.
Reengagement intervention implementation characteristics.
| Study | Income | Tracing method | Trace by telephone call | Trace by letter | Trace by home visit | Trace by email | Trace by nonprimary visit* | Support strategy | Tracer | Tracing attempts | Time to tracing | Control | Outcome time point | Time point start date |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
| LMIC | In-person | No | No | Yes | No | No | Peer | 1 or 2 | Same day as missed apt | None | 18 months or longer | after LTFU | |
|
| LMIC | In-person | No | No | Yes | No | No | Outreach worker | 1 | None | Unknown | |||
|
| LMIC | In-person + call | Yes | No | Yes | No | No | Outreach worker | ≥3 | 1 w after LFTU | None | 3 months | ||
|
| LMIC | In-person + call + reengagement support | Yes | No | Yes | No | No | visit escort | Peer | ≥3 | 15 m (median) after LTFU | None | 18 months or longer | |
|
| LMIC | In-person | No | No | Yes | No | No | Peer | SOC (no tracing) | 12 months | after sampling | |||
|
| LMIC | In-person + call + reengagement support | Yes | No | Yes | No | Yes | visit escort | Peer | None | 6 months | |||
|
| LMIC | In-person + call | Yes | No | Yes | No | No | Peer | None | 3 months or less | ||||
|
| LMIC | In-person + call | Yes | No | Yes | No | No | Lay HCW | 1 or 2 | None | 3 months or less | after home visit | ||
|
| LMIC | Phone/text/email/mail | Yes | No | No | No | No | SW | ≥3 | None | 6 months | |||
|
| LMIC | Phone/text/email/mail | Yes | No | No | No | No | Lay HCW | 1 | None | 3 months or less | after intervention enrollment | ||
|
| LMIC | In-person + call | Yes | No | Yes | No | No | Outreach worker | 5–90 days after missed apt | SOC (no tracing) | 3 months or less | |||
|
| LMIC | In-person + call | Yes | No | Yes | No | No | Lay HCW | ≥3 | None | 3 months or less | after contact | ||
|
| LMIC | In-person | No | No | Yes | No | No | Community HCW | 1 | None | Unknown | |||
|
| LMIC | In-person + call | Yes | No | Yes | No | No | Lay HCW | None | 3 months | after tracking | |||
|
| LMIC | In-person | No | No | Yes | No | No | Lay HCW | Early as 8 days after LTFU | SOC (Patients not found) | 12 months | After missed appointment | ||
|
| LMIC | In-person + call | Yes | No | Yes | No | No | Lay HCW | ≥3 | >3 weeks after missed appointment | None | Unknown | ||
|
| HIC | In-person + call | Yes | Yes | Yes | No | No | Outreach coordinator | None | Unknown | ||||
|
| HIC | In-person + call + reengagement support | Yes | No | No | Yes | Yes | visit escort, transportation assistance, or inpatient visits | Linkage specialist/case manager | ≥3 | SOC (no tracing) | 12 months | ||
|
| HIC | Call + reengagement support | Yes | No | No | No | No | rescheduling new appointment | HCW | None | 12 months | after intervention enrollment | ||
|
| HIC | In-person + call | Yes | Yes | No | No | Yes | Patient navigator/case manager | None | 3 months or less | after contact | |||
|
| HIC | Phone/text/email/mail | Yes | No | No | No | No | 1 or 2 | None | Unknown | ||||
|
| HIC | In-person | Disease intervention specialist | SOC (no tracing) | 3 months or less | after randomization | ||||||||
|
| HIC | Phone/text/email/mail | Yes | Yes | No | Yes | No | SW | None | Unknown | ||||
|
| HIC | In-person + call + reengagement support | Yes | Yes | No | No | No | Transportation assistance, and mental health and substance use services | Patient navigator/case manager | None | 12 months | |||
|
| HIC | In-person + call + reengagement support | Yes | Yes | Yes | Yes | No | rescheduling new appointment | Field epidemiologist | 1 | None | 3 months or less | after intervention enrollment | |
|
| HIC | In-person + call | Yes | No | No | No | Yes | Program coordinator | At attendance for non-HIV care | None | 3 months | after alert | ||
|
| HIC | EMR alert + provider decision support | No | HCW | SOC (no tracing) | 6 months | ||||||||
|
| HIC | Phone/text/email/mail | Yes | No | No | No | No | None | 6 months | |||||
|
| HIC | In-person + call | Yes | Yes | Yes | Yes | No | SOC (no tracing) | 18 months or longer | After tracking | ||||
|
| HIC | In-person + call | Yes | No | No | No | Yes | HCW/SW | SOC (no tracing) | 6 months | After tracking | |||
|
| HIC | Phone/text/email/mail | Yes | Yes | No | Yes | No | Retention specialist | ≥3 | Unspecified; out of care defined by a gap of 6 or more months | None | 6 months | ||
|
| HIC | In-person + call | Yes | Yes | Yes | No | No | Disease intervention specialist | None | 6 months | ||||
|
| HIC | In-person + call | Yes | Yes | Yes | No | No | Case workers | None | 12 months | ||||
|
| HIC | In-person + call | Yes | Yes | Yes | Yes | No | Case workers | None | 12 months | ||||
|
| HIC | In-person + call | Yes | No | Yes | No | No | Patient navigator | SOC (no tracing) | 18 months or longer | ||||
|
| HIC | In-person | No | Disease intervention specialist | SOC (no tracing) | 3 months or less | after randomization | |||||||
|
| HIC | In-person + call + reengagement support | Yes | Yes | Yes | Yes | No | Assist scheduling and emergency referral | Navigator | ≥3 | None | 12 months | after intervention enrollment |
EMR, electronic medical record; HCW, healthcare worker; HIC, high-income country; LMIC, low- and middle-income country; LTFU, lost to follow-up; SOC, standard of care; SW, xxxx.
Risk of biases in the included RCTs.
| Study | Outcome | Sequence Generation | Allocation Concealment | Blinding Participants/Personnel | Blinding Outcome Assessor | Attrition Bias | Selective Reporting | Other Bias | Overall ROB |
|---|---|---|---|---|---|---|---|---|---|
| Udeagu 2019 | Return to care | Unclear risk | Unclear risk | Unclear risk | Unclear risk | Low risk | High Risk | Low risk | Some concerns |
| Villanueva 2019 | Return to care | Unclear risk | Unclear risk | Unclear risk | Unclear risk | Unclear risk | Low Risk | Low risk | Some concerns |
| Villanueva 2019 | Viral suppression | Unclear risk | Unclear risk | Unclear risk | Unclear risk | Unclear risk | Low Risk | Low risk | Some concerns |
| Fox 2018 | Return to care | Low risk | Unclear risk | Unclear risk | Unclear risk | Low risk | Low Risk | Low risk | Low risk |
| Fox 2018 | Retention in Care | Low risk | Unclear risk | Unclear risk | Unclear risk | Low risk | Low Risk | Low risk | Low risk |
| Beres 2019 | Return to care | Low risk | Unclear risk | Unclear risk | Unclear risk | Low risk | Low Risk | Low risk | Low risk |
| Bershetyn 2017 | Return to care | Low risk | Unclear risk | Unclear risk | Unclear risk | Low risk | Low Risk | Low risk | Low risk |
| Fanfair 2019 | Return to care | Unclear risk | Unclear risk | Unclear risk | Unclear risk | Unclear risk | Low Risk | Low risk | Some concerns |
RCT, randomized controlled trial; ROB, risk of bias.
Risk of biases in the included cohort studies that had a control group.
| Study | Outcome | Selection | Comparability | Outcome | Total | Overall ROB |
|---|---|---|---|---|---|---|
| Magnus 2012 | Return to care | **** | * | *** | ******** | Good Quality |
| Magnus 2012 | Retention in Care | **** | * | *** | ******* | Good Quality |
| Bove 2015 | Return to care | *** | * | *** | ****** | Good quality |
| Bove 2015 | Viral suppression | ** | * | ** | ***** | Fair Quality |
| Bove 2015 | Retention in Care | *** | * | *** | ****** | Good Quality |
| Rebeiro 2017 | Return to care | ** | * | * | **** | Poor Quality |
| Sharp 2019 | Return to care | ** | * | *** | ***** | Fair Quality |
| Saafir-Callaway 2020 | Retention in Care | **** | * | *** | ******* | Good Quality |
| Saafir-Callaway 2020 | Retention in Care | **** | *** | ******* | Good Quality | |
| Saafir-Callaway 2020 | Viral suppression | **** | * | ** | ****** | Good Quality |
ROB, risk of bias.
PRECIS criteria/score.
| Study | Eligibility | Recruitment/cohort selection | Setting | Organization | Flexibility: delivery | Flexibility: adherence | Follow-up | Primary Outcome | Primary Analysis |
|---|---|---|---|---|---|---|---|---|---|
| Beres 2019 | 5 | 5 | 5 | 5 | 4 | 5 | 5 | 5 | 5 |
| Bershetyn 2015 | 5 | 5 | 5 | 4 | 5 | 5 | 5 | 5 | 5 |
| Bove 2015 | 5 | 4 | 4 | 4 | 5 | 5 | 5 | 5 | 5 |
| Fanfair 2019 | 4 | 5 | 5 | 2 | 5 | 5 | 5 | 5 | 5 |
| Fox 2018 | 4 | 5 | 4 | 4 | 4 | 5 | 5 | 5 | 4 |
| Magnus 2012 | 5 | 5 | 5 | 4 | 5 | 5 | 5 | 5 | NA |
| Rebeiro 2017 | 4 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 3 |
| Udeagu 2019 | 5 | 5 | 5 | 4 | 4 | 5 | 5 | 5 | 4 |
| Villanueva 2019 | 3 | 5 | 5 | 3 | 5 | 5 | 5 | 5 | 5 |
| Sharp 2019 | 5 | 4 | 3 | 4 | 5 | 5 | 5 | 5 | 3 |
*Darker colors represent pragmatic approaches; lighter colors represent explanatory approaches.
NA, not applicable.
Reengagement program outcome: Proportion of all patients who were LTFU returned to the clinic by subgroups.
| Subgroups | Number of studies | Proportion returned (95% CI) | I-squared*** | |
|---|---|---|---|---|
|
| 26 | 0.39 (0.31, 0.47) | 0.001 | 99.70% |
|
| ||||
| Observational | 22 | 0.39 (0.30, 0.48) | 0.001 | 99.70% |
| Randomized | 4 | 0.36 (0.20, 0.52) | 0.001 | 99.40% |
|
| ||||
| High income | 14 | 0.41 (0.29, 0.52) | 0.001 | 99.30% |
| Low–middle income | 12 | 0.37 (0.24, 0.49) | 0.001 | 99.80% |
|
| ||||
| Phone/text/email/mail | 3 | 0.40 (0.10, 0.69) | 0.001 | 98.80% |
| In-person tracing | 5 | 0.37 (0.14, 0.59) | 0.001 | 99.80% |
| In-person tracing + Call | 11 | 0.37 (0.25, 0.49) | 0.001 | 99.40% |
| Call + reengagement support | 0 | ---- | ---- | ---- |
| EMR alert + decision support | 1 | 0.85 (0.81, 0.89) | ---- | ---- |
| In-person tracing + Call + reengagement support | 6 | 0.35 (0.25, 0.45) | 0.001 | 98.70% |
|
| ||||
| Tracing started at 30 days or sooner | 3 | 0.31 (0.01, 0.64) | 0.001 | 99.80% |
| Tracing started after 30 days | 1 | 0.27 (0.25, 0.28) | ---- | ---- |
| Unknown | 22 | 0.40 (0.32, 0.49) | 0.001 | 99.40% |
|
| ||||
| 3 months or less | 10 | 0.45 (0.32, 0.59) | 0.001 | 99.40% |
| 6 months | 5 | 0.47 (0.28, 0.66) | 0.001 | 99.30% |
| 12 months | 6 | 0.33 (0.13, 0.54) | 0.001 | 99.80% |
| 18 months or longer | 3 | 0.17 (0.07, 0.28) | 0.001 | 98.70% |
| Unknown | 2 | 0.33 (0.10, 0.55) | 0.001 | 87.00% |
|
| ||||
| 1 or more missed monthly or biweekly visits | 5 | 0.48 (0.23, 0.73) | 0.001 | 99.80% |
| No visit in 3 < 6 months | 7 | 0.29 (0.18, 0.40) | 0.001 | 99.20% |
| No visit in 6 < 12 months | 7 | 0.47 (0.33, 0.62) | 0.001 | 99.00% |
| No visit in 12 months or longer | 6 | 0.32 (0.13, 0.52) | 0.001 | 99.50% |
| Unknown duration | 1 | 0.38 (0.37–0.40) | ---- | ---- |
|
| ||||
| 1 | 2 | 0.48 (0.01, 0.99) | 0.001 | 99.20% |
| 2 | 2 | 0.09 (0.07, 0.11) | 0.192 | 41.20% |
| 3 or more | 6 | 0.35 (0.21, 0.49) | 0.001 | 99.40% |
| Unknown | 16 | 0.43 (0.34, 0.52) | 0.001 | 99.50% |
|
| ||||
| Peer | 5 | 0.25 (0.15, 0.36) | 0.001 | 99.30% |
| Social worker | 9 | 0.30 (0.17, 0.43) | 0.001 | 99.30% |
| Healthcare worker (i.e., nurse, physician) | 12 | 0.51 (0.40, 0.61) | 0.001 | 99.30% |
|
| ||||
| Active (tracing included any support) | 6 | 0.35 (0.25, 0.45) | 0.001 | 98.70% |
| Passive (no support reported) | 20 | 0.40 (0.30, 0.49) | 0.001 | 99.70% |
*Random effect model.
**P value is for Heterogeneity. H0: Variation is only by chance.
***The variation in the proportion (outcome) attributable to heterogeneity.
CI, confidence interval; EMR, electronic medical record; LTFU, lost to follow-up.
GRADE evidence profile.
| Certainty assessment | № of patients | Effect | Certainty | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| № of studies | Study design | Risk of bias | Inconsistency | Indirectness | Imprecision | Other | reengagement interventions (tracing or certain types of interventions) | SOC or not tracing | Relative (95% CI) | Absolute (95% CI) | ||
|
| ||||||||||||
| 9 | randomized trials | not serious | very serious a | not serious | not serious | none | 16,924/26,749 (63.3%) | 24,168/61,415 (39.4%) | ⨁⨁◯◯ LOW | |||
|
| ||||||||||||
| 6 | randomized trials | not serious | very seriousa | not serious | not serious | none | 16,499/25,557 (64.6%) | 23,695/60,114 (39.4%) | ⨁⨁◯◯ LOW | |||
|
| ||||||||||||
| 3 | Observational studiesb | not serious | seriousa | not serious | not serious | none | 425/1,192 (35.7%) | 473/1,301 (36.4%) | ⨁◯◯◯ VERY LOW | |||
|
| ||||||||||||
| 3 | randomized trials | not serious | seriousc | not serious | seriousd | none | 15,802/24,078 (65.6%) | 22,214/55,440 (40.1%) | ⨁⨁◯◯ LOW | |||
|
| ||||||||||||
| 6 | randomized trials | not serious | not serious | not serious | not serious | none | 1122/2671 (42.0%) | 1954/5975 (32.7%) | ⨁⨁⨁⨁ HIGH | |||
|
| ||||||||||||
| 2 | observational studiesb | seriouse | not serious | seriousf | not serious | none | 12,397/16,322 (76.0%) | 9,839/20,390 (48.3%) | ⨁◯◯◯ VERY LOW | |||
CI, confidence interval; HIC, high-income country; LMIC, low- and middle-income country; LTFU, lost to follow-up; RCT, randomized controlled trial; RR, risk ratio; SOC, standard of care.